Track protection status across key markets to assess launch feasibility.
It is formulated by 3 pharmaceutical companies such as VIVUS LLC, ACTAVIS LABS FL INC, DR REDDYS LABS SA. It is marketed under 2 brand names, including QSYMIA, PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE. Available in 4 different strengths, such as EQ 15MG BASE;92MG, EQ 11.25MG BASE;69MG, EQ 7.5MG BASE;46MG and others, and administered through 1 route including CAPSULE, EXTENDED RELEASE;ORAL.
API availability: Loading API feasibility...
Licensing: 3 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
Strength | Route of Administration | Companies | Latest Approval Date |
---|
Patents approved by the FDA for the ingredient
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
---|---|---|---|---|---|
{"application_id":"44712","ingredient":"PHENTERMINE HYDROCHLORIDE; TOPIRAMATE","trade_name":"QSYMIA","family_id":"3be4f2e622cd42bcbd3d","publication_number":"US8895057B2","cleaned_patent_number":"8895057","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-06-09","publication_date":"2014-11-25","legal_status":"Granted"} | US8895057B2 | 25 Nov, 2014 | Granted | 09 Jun, 2028 | |
{"application_id":"44747","ingredient":"PHENTERMINE HYDROCHLORIDE; TOPIRAMATE","trade_name":"QSYMIA","family_id":"3be4f2e622cd42bcbd3d","publication_number":"US8895058B2","cleaned_patent_number":"8895058","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-06-09","publication_date":"2014-11-25","legal_status":"Granted"} | US8895058B2 Formulation | 25 Nov, 2014 | Granted | 09 Jun, 2028 | |
{"application_id":"44748","ingredient":"PHENTERMINE HYDROCHLORIDE; TOPIRAMATE","trade_name":"QSYMIA","family_id":"3be4f2e622cd42bcbd3d","publication_number":"US9011905B2","cleaned_patent_number":"9011905","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-06-09","publication_date":"2015-04-21","legal_status":"Granted"} | US9011905B2 Formulation | 21 Apr, 2015 | Granted | 09 Jun, 2028 | |
{"application_id":"44749","ingredient":"PHENTERMINE HYDROCHLORIDE; TOPIRAMATE","trade_name":"QSYMIA","family_id":"3be4f2e622cd42bcbd3d","publication_number":"US9011906B2","cleaned_patent_number":"9011906","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-06-09","publication_date":"2015-04-21","legal_status":"Granted"} | US9011906B2 | 21 Apr, 2015 | Granted | 09 Jun, 2028 | |
{"application_id":"44745","ingredient":"PHENTERMINE HYDROCHLORIDE; TOPIRAMATE","trade_name":"QSYMIA","family_id":"3be4f2e622cd42bcbd3d","publication_number":"US8580298B2","cleaned_patent_number":"8580298","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-05-15","publication_date":"2013-11-12","legal_status":"Granted"} | US8580298B2 Formulation | 12 Nov, 2013 | Granted | 15 May, 2029 | |
{"application_id":"44746","ingredient":"PHENTERMINE HYDROCHLORIDE; TOPIRAMATE","trade_name":"QSYMIA","family_id":"3be4f2e622cd42bcbd3d","publication_number":"US8580299B2","cleaned_patent_number":"8580299","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-06-14","publication_date":"2013-11-12","legal_status":"Granted"} | US8580299B2 | 12 Nov, 2013 | Granted | 14 Jun, 2029 |
Latest clinical trials and research studies for this ingredient
NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
---|
Manufacturing Locations
Unlock access to all suppliers of Phentermine Hydrochloride; Topiramate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.